Pfizer Inc.’s (PFE) supplemental new drug applications for XELJANZ 5 mg and XELJANZ XR 11 mg for the treatment of adult patients with active psoriatic arthritis await the FDA decision, which is expected in December. An FDA panel voted in favor of XELJANZ 5 mg and XELJANZ XR 11 for active psoriatic arthritis in August of this year. XELJANZ is an immediate release tablet that releases medication into the bloodstream over the course of several hours, and is taken twice daily. XELJANZ XR is an extended release tablet that releases medication into the bloodstream over the course of a day, and is taken only once a day. XELJANZ and XELJANZ XR are already approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis. The drugs netted sales of $935 million in the first nine months of 2017 and $927 million for full year 2016.PFE closed Tuesday’s (Nov.28) trading at $35.85, up 1.01%.